Current status and prospective of neoadjuvant immune checkpoint inhibitors for resectable non-small cell lung cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Rusi ^1,2,3 ,  ZHANG Lanjun ^1,2

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510000, P.R.China;
2. Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, 510000, P.R.China;
3. Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510000, P.R.China;

Corresponding author：

ZHANG Lanjun, Email: zhanglj@sysucc.org.cn

Keywords：

Non-small cell lung cancer; neoadjuvant therapy; immune checkpoint inhibitor; review

DOI：

10.7507/1007-4848.202001058

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Surgery remains as the primary definitive therapy for resectable non-small cell lung cancer (NSCLC) currently. However, quite a few NSCLC patients, especially in the later stage, suffered tumor recurrence after resection. Safer and more effective perioperative treatment is urgently needed to reduce the recurrence risk after NSCLC surgery. Immune checkpoint inhibitors can effectively prevent tumor immune evasion and have been shown to be a feasible, safe and effective neoadjuvant therapy for resectable NSCLC. Nevertheless, certain crucial problems, including the final effect on NSCLC recurrence, the selection of beneficial group and optimal treatment protocol are yet unsolved. Fortunately, several phase Ⅲ randomized controlled trials are ongoing to answer these questions and will hopefully provide stronger evidence.

Citation： ZHANG Rusi, ZHANG Lanjun. Current status and prospective of neoadjuvant immune checkpoint inhibitors for resectable non-small cell lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2020, 27(11): 1348-1352. doi: 10.7507/1007-4848.202001058 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2016, 11(1): 39-51.
3.	Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 2010, 28(1): 35-42.
4.	Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
5.	Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 2007, 25(12): 1553-1561.
6.	National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 2.2019. 2018, 2019(2019.1.4).
7.	Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26(21): 3552-3559.
8.	Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570.
9.	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
10.	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
11.	Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833.
12.	Hellmann MD, Chaft JE, William WJ, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol, 2014, 15(1): e42-e50.
13.	Blumenthal GM, Bunn PJ, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol, 2018, 13(12): 1818-1831.
14.	Li N, Ying J, Tao X, et al. Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC). J Thorac Oncol, 2019, 37(15_suppl): 8531.
15.	Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase Ⅰ study, MK3475-223. J Clin Oncol, 2019, 37(15_suppl): 8534-8534.
16.	Shu CA, Grigg C, Chiuzan C, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol, 2018, 36(15_suppl): 8532-8532.
17.	Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol, 2019, 37(15_suppl): 8504.
18.	Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol, 2019, 37(15_suppl): 8503.
19.	Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage ⅢA resectable non-small-cell lung cancer (NSCLC): A phaseⅡ multicenter exploratory study—Final data of patients who underwent surgical assessment. J Clin Oncol, 2019, 37(15_suppl): 8509.
20.	Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 nlockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
21.	Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
22.	Sepesi B, Cascone T, William W, et al. OA13.06 surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer - NEOSTAR Study. J Thorac Oncol, 2019, 14(10): S241-S242.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2016, 11(1): 39-51.
3. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 2010, 28(1): 35-42.
4. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
5. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 2007, 25(12): 1553-1561.
6. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 2.2019. 2018, 2019(2019.1.4).
7. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26(21): 3552-3559.
8. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570.
9. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
11. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833.
12. Hellmann MD, Chaft JE, William WJ, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol, 2014, 15(1): e42-e50.
13. Blumenthal GM, Bunn PJ, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol, 2018, 13(12): 1818-1831.
14. Li N, Ying J, Tao X, et al. Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC). J Thorac Oncol, 2019, 37(15_suppl): 8531.
15. Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase Ⅰ study, MK3475-223. J Clin Oncol, 2019, 37(15_suppl): 8534-8534.
16. Shu CA, Grigg C, Chiuzan C, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol, 2018, 36(15_suppl): 8532-8532.
17. Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol, 2019, 37(15_suppl): 8504.
18. Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol, 2019, 37(15_suppl): 8503.
19. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage ⅢA resectable non-small-cell lung cancer (NSCLC): A phaseⅡ multicenter exploratory study—Final data of patients who underwent surgical assessment. J Clin Oncol, 2019, 37(15_suppl): 8509.
20. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 nlockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
21. Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
22. Sepesi B, Cascone T, William W, et al. OA13.06 surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer - NEOSTAR Study. J Thorac Oncol, 2019, 14(10): S241-S242.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Current status and prospective of neoadjuvant immune checkpoint inhibitors for resectable non-small cell lung cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content